Dr. Vargas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 Parnassus Ave
San Francisco, CA 94143Phone+1 415-476-7500Fax+1 415-502-6361
Education & Training
University of California (San Francisco)Residency, Psychiatry, 1997 - 2001
University of California, Irvine, School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1998 - 2026
Publications & Presentations
PubMed
- 29 citationsReduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humansNarender R. Gavva, Robert W Sandrock, Gregory E. Arnold, Michael T. Davis, Edwin Lamas
Scientific Reports. 2019-12-23 - 28 citationsPhase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure...Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Marissa Herbots, Yumi Kubo
Cephalalgia. 2019-01-01 - 59 citationsPhase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Lucy Yan, Brian Smith
Clinical Pharmacology and Therapeutics. 2018-05-01
Press Mentions
CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s DiseaseNovember 9th, 2021- CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating That Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative DiseaseMarch 15th, 2021
- CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative DiseaseSeptember 15th, 2020
Grant Support
- Membrane Trafficking Regulation Of Dopamine ReceptorsNational Institute Of Mental Health2003–2006
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
